Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications

(2010) Mickaël Hiligsmann et al.   CALCIFIED TISSUE INTERNATIONAL

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

(2010) B. Jönsson et al.   OSTEOPOROSIS INTERNATIONAL

Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates

(2010) Becky A. Briesacher et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

(2009) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis

(2009) I. Imaz et al.   OSTEOPOROSIS INTERNATIONAL

Fracture Outcomes Related to Persistence and Compliance With Oral Bisphosphonates

(2008) Arlene M Gallagher et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Incorporating adherence into health economic modelling of osteoporosis

(2008) O. Ström et al.   OSTEOPOROSIS INTERNATIONAL